The Role of Molecular Imaging in the Assessment of Cardiac Amyloidosis: State-of-the-Art

Cristina       Popescu; Irene    A.   Burger
doi:10.2174/1874471013666200611105856
Abstract

Cardiac amyloidosis is a progressive infiltrative disease for which new treatments are now available. As therapy should be started as early as possible to avoid complications such as restrictive cardiomyopathy, arrhythmias and heart failure, a prompt and reliable diagnosis by means of non-invasive tests would be highly warranted. Electrocardiography, echocardiography and cardiac magnetic resonance imaging are all used in the evaluation of cardiac amyloidosis with varying diagnostic and prognostic accuracy, but none of these modalities can effectively differentiate the cardiac amyloid subtypes. We aim to highlight the most relevant findings in the literature of molecular imaging in the assessment of patients with cardiac amyloidosis and to underline future clinical perspective. We performed multiple searches using Pub-Med databases in order to find important original articles on the role of molecular imaging in the assessment of patients affected by CA. Several search terms were used, such as “cardiac amyloidosis”; “Light-chain amyloidosis”; “Transthyretin amyloid cardiomyopathy”; “bone scintigraphy”; “single photon emission tomography” or “SPECT”; “Positron emission tomography or PET”, and “cardiac imaging”. All radiopharmaceuticals tracing cardiac amyloidosis were also included. Several studies about the role of SPECT with bone-seeking tracer (47 articles) and innervation tracer (9 articles) in the work-up of CA, as well as new PET amyloid-binding (14 articles) and bone radiotracer (4 articles) have been reviewed and discussed. Molecular imaging represents a sensitive tool for early assessment of both amyloid burden and cardiac innervation, to differentiate between subtypes and to monitor disease burden, disease progression, and potential response to therapy.
Keywords: Cardiac amyloidosis, light-chain, transthyretin amyloid cardiomyopathy, bone scintigraphy, SPECT, positron emission tomography.
« Previous Next »
Graphical Abstract

[1] 
Merlini, G.; Bellotti, V. Molecular mechanisms of amyloidosis. N. Engl. J. Med.,  2003, 349(6), 583-596.
[http://dx.doi.org/10.1056/NEJMra023144] [PMID: 12904524] 
[2] 
Falk, R.H. Diagnosis and management of the cardiac amyloidoses. Circulation,  2005, 112(13), 2047-2060.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.104.489187] [PMID: 16186440] 
[3] 
Ruberg, F.L.; Berk, J.L. Transthyretin (TTR) cardiac amyloidosis. Circulation,  2012, 126(10), 1286-1300.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.111.078915] [PMID: 22949539] 
[4] 
Brenner, D.A.; Jain, M.; Pimentel, D.R.; Wang, B.; Connors, L.H.; Skinner, M.; Apstein, C.S.; Liao, R. Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circ. Res.,  2004, 94(8), 1008-1010.
[http://dx.doi.org/10.1161/01.RES.0000126569.75419.74] [PMID: 15044325] 
[5] 
Grogan, M.; Dispenzieri, A.; Gertz, M.A. Light-chain cardiac amyloidosis: strategies to promote early diagnosis and cardiac response. Heart,  2017, 103(14), 1065-1072.
[http://dx.doi.org/10.1136/heartjnl-2016-310704] [PMID: 28456755] 
[6] 
Seferović, P.M.; Polovina, M.; Bauersachs, J.; Arad, M.; Gal, T.B.; Lund, L.H.; Felix, S.B.; Arbustini, E.; Caforio, A.L.P.; Farmakis, D.; Filippatos, G.S.; Gialafos, E.; Kanjuh, V.; Krljanac, G.; Limongelli, G.; Linhart, A.; Lyon, A.R.; Maksimović, R.; Miličić, D.; Milinković, I.; Noutsias, M.; Oto, A.; Oto, Ö.; Pavlović, S.U.; Piepoli, M.F.; Ristić, A.D.; Rosano, G.M.C.; Seggewiss, H.; Ašanin, M.; Seferović, J.P.; Ruschitzka, F.; Čelutkiene, J.; Jaarsma, T.; Mueller, C.; Moura, B.; Hill, L.; Volterrani, M.; Lopatin, Y.; Metra, M.; Backs, J.; Mullens, W.; Chioncel, O.; de Boer, R.A.; Anker, S.; Rapezzi, C.; Coats, A.J.S.; Tschöpe, C. Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology. Eur. J. Heart Fail.,  2019, 21(5), 553-576.
[http://dx.doi.org/10.1002/ejhf.1461] [PMID: 30989768] 
[7] 
Rigopoulos, A.G.; Ali, M.; Abate, E.; Torky, A.R.; Matiakis, M.; Mammadov, M.; Melnyk, H.; Vogt, A.; de Vecchis, R.; Bigalke, B.; Wohlgemuth, W.; Mavrogeni, S.; Noutsias, M. Advances in the diagnosis and treatment of transthyretin amyloidosis with cardiac involvement. Heart Fail. Rev.,  2019, 24(4), 521-533.
[http://dx.doi.org/10.1007/s10741-019-09776-3] [PMID: 30790171] 
[8] 
Rapezzi, C.; Lorenzini, M.; Longhi, S.; Milandri, A.; Gagliardi, C.; Bartolomei, I.; Salvi, F.; Maurer, M.S. Cardiac amyloidosis: the great pretender. Heart Fail. Rev.,  2015, 20(2), 117-124.
[http://dx.doi.org/10.1007/s10741-015-9480-0] [PMID: 25758359] 
[9] 
Yilmaz, A.; Kindermann, I.; Kindermann, M.; Mahfoud, F.; Ukena, C.; Athanasiadis, A.; Hill, S.; Mahrholdt, H.; Voehringer, M.; Schieber, M.; Klingel, K.; Kandolf, R.; Böhm, M.; Sechtem, U. Comparative evaluation of left and right ventricular endomyocardial biopsy: differences in complication rate and diagnostic performance. Circulation,  2010, 122(9), 900-909.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.109.924167] [PMID: 20713901] 
[10] 
Rapezzi, C.; Arbustini, E.; Caforio, A.L.P.; Charron, P.; Gimeno-Blanes, J.; Heliö, T.; Linhart, A.; Mogensen, J.; Pinto, Y.; Ristic, A.; Seggewiss, H.; Sinagra, G.; Tavazzi, L.; Elliott, P.M. Diagnostic work-up in cardiomyopathies: bridging the gap between clinical phenotypes and final diagnosis. A position statement from the ESC Working Group on myocardial and pericardial diseases. Eur. Heart J.,  2013, 34(19), 1448-1458.
[http://dx.doi.org/10.1093/eurheartj/ehs397] [PMID: 23211230] 
[11] 
Slart, R.H.J.A.; Glaudemans, A.W.J.M.; Noordzij, W.; Bijzet, J.; Hazenberg, B.P.C.; Nienhuis, H.L.A. Time for new imaging and therapeutic approaches in cardiac amyloidosis. Eur. J. Nucl. Med. Mol. Imaging,  2019, 46(7), 1402-1406.
[http://dx.doi.org/10.1007/s00259-019-04325-4] [PMID: 31016330] 
[12] 
Lekakis, J.; Dimopoulos, M.; Nanas, J.; Prassopoulos, V.; Agapitos, N.; Alexopoulos, G.; Palazis, L.; Kostamis, P.; Stamatelopoulos, S.; Moulopoulos, S. Antimyosin scintigraphy for detection of cardiac amyloidosis. Am. J. Cardiol.,  1997, 80(7), 963-965.
[http://dx.doi.org/10.1016/S0002-9149(97)00558-4] [PMID: 9382020] 
[13] 
Chen, W.; Dilsizian, V. Molecular imaging of amyloidosis: will the heart be the next target after the brain? Curr. Cardiol. Rep.,  2012, 14(2), 226-233.
[http://dx.doi.org/10.1007/s11886-011-0239-5] [PMID: 22193845] 
[14] 
Lee, J.H.; Lee, G.Y.; Kim, S.J.; Kim, K.H.; Jeon, E.S.; Lee, K.H.; Kim, B.T.; Choi, J.Y. Imaging findings and literature review of (18)F-FDG PET/CT in primary systemic AL amyloidosis. Nucl. Med. Mol. Imaging,  2015, 49(3), 182-190.
[http://dx.doi.org/10.1007/s13139-015-0338-0] [PMID: 26279691] 
[15] 
Pelletier-Galarneau, M.; Abikhzer, G.; Giraldeau, G.; Harel, F. Molecular imaging of cardiac amyloidosis. Curr. Cardiol. Rep.,  2019, 21(3), 12.
[http://dx.doi.org/10.1007/s11886-019-1097-9] [PMID: 30815746] 
[16] 
Castaño, A.; Narotsky, D.L.; Hamid, N.; Khalique, O.K.; Morgenstern, R.; DeLuca, A.; Rubin, J.; Chiuzan, C.; Nazif, T.; Vahl, T.; George, I.; Kodali, S.; Leon, M.B.; Hahn, R.; Bokhari, S.; Maurer, M.S. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur. Heart J.,  2017, 38(38), 2879-2887.
[http://dx.doi.org/10.1093/eurheartj/ehx350] [PMID: 29019612] 
[17] 
Sperry, B.W.; Reyes, B.A.; Ikram, A.; Donnelly, J.P.; Phelan, D.; Jaber, W.A.; Shapiro, D.; Evans, P.J.; Maschke, S.; Kilpatrick, S.E.; Tan, C.D.; Rodriguez, E.R.; Monteiro, C.; Tang, W.H.W.; Kelly, J.W.; Seitz, W.H., Jr; Hanna, M. Tenosynovial and Cardiac amyloidosis inpatients undergoing carpaltunnelRelease. J. Am. Coll. Cardiol.,  2018, 72(17), 2040-2050.
[http://dx.doi.org/10.1016/j.jacc.2018.07.092] [PMID: 30336828] 
[18] 
Bengel, F.M. The non-invasive biopsy: molecular imaging for the detection of cardiac involvement in systemic disease. Eur. Heart J. Cardiovasc. Imaging,  2014, 15(11), 1299-1300.
[http://dx.doi.org/10.1093/ehjci/jeu140] [PMID: 25104807] 
[19] 
Slart, R.H.J.A.; Glaudemans, A.W.J.M.; Hazenberg, B.P.C.; Noordzij, W. Imaging cardiac innervation in amyloidosis. J. Nucl. Cardiol.,  2019, 26(1), 174-187.
[http://dx.doi.org/10.1007/s12350-017-1059-9] [PMID: 28887775] 
[20] 
Kula, R.W.; Engel, W.K.; Line, B.R. Scanning for soft-tissue amyloid. Lancet,  1977, 1(8002), 92-93.
[http://dx.doi.org/10.1016/S0140-6736(77)91102-3] [PMID: 63730] 
[21] 
Gillmore, J.D.; Maurer, M.S.; Falk, R.H.; Merlini, G.; Damy, T.; Dispenzieri, A.; Wechalekar, A.D.; Berk, J.L.; Quarta, C.C.; Grogan, M.; Lachmann, H.J.; Bokhari, S.; Castano, A.; Dorbala, S.; Johnson, G.B.; Glaudemans, A.W.; Rezk, T.; Fontana, M.; Palladini, G.; Milani, P.; Guidalotti, P.L.; Flatman, K.; Lane, T.; Vonberg, F.W.; Whelan, C.J.; Moon, J.C.; Ruberg, F.L.; Miller, E.J.; Hutt, D.F.; Hazenberg, B.P.; Rapezzi, C.; Hawkins, P.N. Nonbiopsy Diagnosis of cardiac transthyretin amyloidosis. Circulation,  2016, 133(24), 2404-2412.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.116.021612] [PMID: 27143678] 
[22] 
Treglia, G.; Glaudemans, A.W.J.M.; Bertagna, F.; Hazenberg, B.P.C.; Erba, P.A.; Giubbini, R.; Ceriani, L.; Prior, J.O.; Giovanella, L.; Slart, R.H.J.A. Diagnostic accuracy of bone scintigraphy in the assessment of cardiac transthyretin-related amyloidosis: a bivariate meta-analysis. Eur. J. Nucl. Med. Mol. Imaging,  2018, 45(11), 1945-1955.
[http://dx.doi.org/10.1007/s00259-018-4013-4] [PMID: 29687207] 
[23] 
Aljaroudi, W.A.; Desai, M.Y.; Tang, W.H.; Phelan, D.; Cerqueira, M.D.; Jaber, W.A. Role of imaging in the diagnosis and management of patients with cardiac amyloidosis: state of the art review and focus on emerging nuclear techniques. J. Nucl. Cardiol.,  2014, 21(2), 271-283.
[http://dx.doi.org/10.1007/s12350-013-9800-5] [PMID: 24347127] 
[24] 
Ferreira, S.G.; Rocha, A.M.; Moreira do Nascimento, O.J.; Mesquita, C.T. Role of (99m)Tc-DPD scintigraphy on discrimination of familial cardiac amyloidosis. Int. J. Cardiol.,  2016, 203, 885-887.
[http://dx.doi.org/10.1016/j.ijcard.2015.11.002] [PMID: 26605689] 
[25] 
Perugini, E.; Guidalotti, P.L.; Salvi, F.; Cooke, R.M.; Pettinato, C.; Riva, L.; Leone, O.; Farsad, M.; Ciliberti, P.; Bacchi-Reggiani, L.; Fallani, F.; Branzi, A.; Rapezzi, C. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J. Am. Coll. Cardiol.,  2005, 46(6), 1076-1084.
[http://dx.doi.org/10.1016/j.jacc.2005.05.073] [PMID: 16168294] 
[26] 
Gallini, C.; Tutino, F.; Martone, R.; Ciaccio, A.; Costanzo, E.N.; Taborchi, G.; Morini, S.; Bartolini, S.; Farsetti, S.; Di Mario, C.; Perfetto, F.; Cappelli, F. Semi-quantitative indices of cardiac uptake in patients with suspected cardiac amyloidosis undergoing 99mTc-HMDP scintigraphy. J. Nucl. Cardiol.,  2021, 28(1), 90-99.
[http://dx.doi.org/10.1007/s12350-019-01643-w] [PMID: 30767162] 
[27] 
Pradel, S.; Brun, S.; Victor, G.; Pascal, P.; Fournier, P.; Ribes, D. Pattern of myocardial 99mTc-HMDP uptake and impact on myocardial function in patients with transthyretin cardiac amyloidosis. J. Nucl. Cardiol.,  2020, 27(1), 96-105.
[http://dx.doi.org/10.1007/s12350-018-1316-6] [PMID: 29881913] 
[28] 
Rapezzi, C.; Quarta, C.C.; Guidalotti, P.L.; Pettinato, C.; Fanti, S.; Leone, O.; Ferlini, A.; Longhi, S.; Lorenzini, M.; Reggiani, L.B.; Gagliardi, C.; Gallo, P.; Villani, C.; Salvi, F. Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis. JACC Cardiovasc. Imaging,  2011, 4(6), 659-670.
[http://dx.doi.org/10.1016/j.jcmg.2011.03.016] [PMID: 21679902] 
[29] 
Glaudemans, A.W.J.M.; van Rheenen, R.W.J.; van den Berg, M.P.; Noordzij, W.; Koole, M.; Blokzijl, H.; Dierckx, R.A.; Slart, R.H.; Hazenberg, B.P. Bone scintigraphy with (99m)technetium-hydroxymethylene diphosphonate allows early diagnosis of cardiac involvement in patients with transthyretin-derived systemic amyloidosis. Amyloid,  2014, 21(1), 35-44.
[http://dx.doi.org/10.3109/13506129.2013.871250] [PMID: 24455993] 
[30] 
Bokhari, S.; Castaño, A.; Pozniakoff, T.; Deslisle, S.; Latif, F.; Maurer, M.S. (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging,  2013, 6(2), 195-201.
[http://dx.doi.org/10.1161/CIRCIMAGING.112.000132] [PMID: 23400849] 
[31] 
Castano, A.; Haq, M.; Narotsky, D.L.; Goldsmith, J.; Weinberg, R.L.; Morgenstern, R.; Pozniakoff, T.; Ruberg, F.L.; Miller, E.J.; Berk, J.L.; Dispenzieri, A.; Grogan, M.; Johnson, G.; Bokhari, S.; Maurer, M.S. Multicenter study of planar technetium 99m pyrophosphate cardiac imaging: predicting survival for patients with ATTR cardiac amyloidosis. JAMA Cardiol.,  2016, 1(8), 880-889.
[http://dx.doi.org/10.1001/jamacardio.2016.2839] [PMID: 27557400] 
[32] 
Flaherty, K.R.; Morgenstern, R.; Pozniakoff, T.; DeLuca, A.; Castano, A.; Maurer, M.S. 99mTechnetium pyrophosphate scintigraphy with cadmium zinc telluride cameras is a highly sensitive and specific imaging modality to diagnose transthyretin cardiac amyloidosis. J. Nucl. Cardiol.,  2020, 27(2), 371-338.
[http://dx.doi.org/10.1007/s12350-019-01831-8] [PMID: 31463816] 
[33] 
Ramsay, S.C.; Lindsay, K.; Fong, W.; Patford, S.; Younger, J.; Atherton, J. Tc-HDP quantitative SPECT/CT in transthyretin cardiac amyloid and the development of a reference interval for myocardial uptake in the non-affected population. Eur J Hybrid Imaging,  2018, 2(1), 17.
[http://dx.doi.org/10.1186/s41824-018-0035-1] [PMID: 30175320] 
[34] 
Caobelli, F.; Braun, M.; Haaf, P.; Wild, D.; Zellweger, M.J. Quantitative 99mTc-DPD SPECT/CT in patients with suspected ATTR cardiac amyloidosis: Feasibility and correlation with visual scores. J. Nucl. Cardiol.,  2020, 27(5), 1456-1463.
[http://dx.doi.org/10.1007/s12350-019-01893-8] [PMID: 31538322] 
[35] 
Rapezzi, C.; Quarta, C.C.; Guidalotti, P.L.; Longhi, S.; Pettinato, C.; Leone, O.; Ferlini, A.; Salvi, F.; Gallo, P.; Gagliardi, C.; Branzi, A. Usefulness and limitations of 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy. Eur. J. Nucl. Med. Mol. Imaging,  2011, 38(3), 470-478.
[http://dx.doi.org/10.1007/s00259-010-1642-7] [PMID: 21069320] 
[36] 
de Haro-del Moral, F.J.; Sánchez-Lajusticia, A.; Gómez-Bueno, M.; García-Pavía, P.; Salas-Antón, C.; Segovia-Cubero, J. Role of cardiac scintigraphy with ⁹⁹mTc-DPD in the differentiation of cardiac amyloidosis subtype. Rev. Esp. Cardiol. (Engl. Ed.),  2012, 65(5), 440-446.
[http://dx.doi.org/10.1016/j.rec.2011.12.016] [PMID: 22464102] 
[37] 
Hutt, D.F.; Quigley, A.M.; Page, J.; Hall, M.L.; Burniston, M.; Gopaul, D.; Lane, T.; Whelan, C.J.; Lachmann, H.J.; Gillmore, J.D.; Hawkins, P.N.; Wechalekar, A.D. Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis. Eur. Heart J. Cardiovasc. Imaging,  2014, 15(11), 1289-1298.
[http://dx.doi.org/10.1093/ehjci/jeu107] [PMID: 24939945] 
[38] 
Moore, P.T.; Burrage, M.K.; Mackenzie, E.; Law, W.P.; Korczyk, D.; Mollee, P. The utility of 99mTc-DPD scintigraphy in the diagnosis of cardiac amyloidosis: an australian experience. Heart Lung Circ.,  2017, 26(11), 1183-1190.
[http://dx.doi.org/10.1016/j.hlc.2016.12.017] [PMID: 28256403] 
[39] 
Quarta, C.C.; Guidalotti, P.L.; Longhi, S.; Pettinato, C.; Leone, O.; Ferlini, A.; Biagini, E.; Grigioni, F.; Bacchi-Reggiani, M.L.; Lorenzini, M.; Milandri, A.; Branzi, A.; Rapezzi, C. Defining the diagnosis in echocardiographically suspected senile systemic amyloidosis. JACC Cardiovasc. Imaging,  2012, 5(7), 755-758.
[http://dx.doi.org/10.1016/j.jcmg.2012.02.015] [PMID: 22789945] 
[40] 
Hutt, D.F.; Fontana, M.; Burniston, M.; Quigley, A-M.; Petrie, A.; Ross, J.C.; Page, J.; Martinez-Naharro, A.; Wechalekar, A.D.; Lachmann, H.J.; Quarta, C.C.; Rezk, T.; Mahmood, S.; Sachchithanantham, S.; Youngstein, T.; Whelan, C.J.; Lane, T.; Gilbertson, J.A.; Rowczenio, D.; Hawkins, P.N.; Gillmore, J.D. Prognostic utility of the Perugini grading of 99mTc-DPD scintigraphy in transthyretin (ATTR) amyloidosis and its relationship with skeletal muscle and soft tissue amyloid. Eur. Heart J. Cardiovasc. Imaging,  2017, 18(12), 1344-1350.
[http://dx.doi.org/10.1093/ehjci/jew325] [PMID: 28159995] 
[41] 
Vranian, M.N.; Sperry, B.W.; Hanna, M.; Hachamovitch, R.; Ikram, A.; Brunken, R.C.; Jaber, W.A. Technetium pyrophosphate uptake in transthyretin cardiac amyloidosis: Associations with echocardiographic disease severity and outcomes. J. Nucl. Cardiol.,  2018, 25(4), 1247-1256.
[http://dx.doi.org/10.1007/s12350-016-0768-9] [PMID: 28050864] 
[42] 
Longhi, S.; Guidalotti, P.L.; Quarta, C.C.; Gagliardi, C.; Milandri, A.; Lorenzini, M.; Potena, L.; Leone, O.; Bartolomei, I.; Pastorelli, F.; Salvi, F.; Rapezzi, C. Identification of TTR-related subclinical amyloidosis with 99mTc-DPD scintigraphy. JACC Cardiovasc. Imaging,  2014, 7(5), 531-532.
[http://dx.doi.org/10.1016/j.jcmg.2014.03.004] [PMID: 24831216] 
[43] 
Minutoli, F.; Di Bella, G.; Mazzeo, A.; Donato, R.; Russo, M.; Scribano, E.; Baldari, S. Comparison between (99m)Tc-diphosphonate imaging and MRI with late gadolinium enhancement in evaluating cardiac involvement in patients with transthyretin familial amyloid polyneuropathy. AJR Am. J. Roentgenol.,  2013, 200(3), 256-265.
[http://dx.doi.org/10.2214/AJR.12.8737] [PMID: 23436870] 
[44] 
Bennani Smires, Y.; Victor, G.; Ribes, D.; Berry, M.; Cognet, T.; Méjean, S.; Huart, A.; Roussel, M.; Petermann, A.; Roncalli, J.; Carrié, D.; Rousseau, H.; Berry, I.; Chauveau, D.; Galinier, M.; Lairez, O. Pilot study for left ventricular imaging phenotype of patients over 65years old with heart failure and preserved ejection fraction: the high prevalence of amyloid cardiomyopathy. Int. J. Cardiovasc. Imaging,  2016, 32(9), 1403-1413.
[http://dx.doi.org/10.1007/s10554-016-0915-z] [PMID: 27240600] 
[45] 
González-López, E.; Gallego-Delgado, M.; Guzzo-Merello, G.; de Haro-Del Moral, F.J.; Cobo-Marcos, M.; Robles, C.; Bornstein, B.; Salas, C.; Lara-Pezzi, E.; Alonso-Pulpon, L.; Garcia-Pavia, P. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur. Heart J.,  2015, 36(38), 2585-2594.
[http://dx.doi.org/10.1093/eurheartj/ehv338] [PMID: 26224076] 
[46] 
Mohamed-Salem, L.; Santos-Mateo, J.J.; Sanchez-Serna, J.; Hernández-Vicente, Á.; Reyes-Marle, R.; Castellón Sánchez, M.I.; Claver-Valderas, M.A.; Gonzalez-Vioque, E.; Haro-Del Moral, F.J.; García-Pavía, P.; Pascual-Figal, D.A. Prevalence of wild type ATTR assessed as myocardial uptake in bone scan in the elderly population. Int. J. Cardiol.,  2018, 270, 192-196.
[http://dx.doi.org/10.1016/j.ijcard.2018.06.006] [PMID: 29903517] 
[47] 
Kristen, A.V.; Scherer, K.; Buss, S.; aus dem Siepen, F.; Haufe, S.; Bauer, R.; Hinderhofer, K.; Giannitsis, E.; Hardt, S.; Haberkorn, U.; Katus, H.A.; Steen, H. Noninvasive risk stratification of patients with transthyretin amyloidosis. JACC Cardiovasc. Imaging,  2014, 7(5), 502-510.
[http://dx.doi.org/10.1016/j.jcmg.2014.03.002] [PMID: 24726252] 
[48] 
Di Bella, G.; Minutoli, F.; Piaggi, P.; Casale, M.; Mazzeo, A.; Zito, C.; Oreto, G.; Baldari, S.; Vita, G.; Pingitore, A.; Khandheria, B.K.; Carerj, S. Quantitative comparison between amyloid deposition detected by (99M)TC-diphosphonate imaging and myocardial deformation evaluated by strain echocardiography in transthyretin-related cardiac amyloidosis. Circ. J.,  2016, 80(9), 1998-2003.
[http://dx.doi.org/10.1253/circj.CJ-16-0209] [PMID: 27477961] 
[49] 
Kristen, A.V.; Haufe, S.; Schonland, S.O.; Hegenbart, U.; Schnabel, P.A.; Röcken, C.; Hardt, S.; Lohse, P.; Ho, A.D.; Haberkorn, U.; Dengler, T.J.; Altland, K.; Katus, H.A. Skeletal scintigraphy indicates disease severity of cardiac involvement in patients with senile systemic amyloidosis. Int. J. Cardiol.,  2013, 164(2), 179-184.
[http://dx.doi.org/10.1016/j.ijcard.2011.06.123] [PMID: 21764155] 
[50] 
Ross, J.C.; Hutt, D.F.; Burniston, M.; Page, J.; Steeden, J.A.; Gillmore, J.D.; Wechalekar, A.D.; Hawkins, P.N.; Fontana, M. Quantitation of 99mTc-DPD uptake in patients with transthyretin-related cardiac amyloidosis. Amyloid,  2018, 25(3), 203-210.
[http://dx.doi.org/10.1080/13506129.2018.1520087] [PMID: 30486686] 
[51] 
Pilebro, B.; Suhr, O.B.; Näslund, U.; Westermark, P.; Lindqvist, P.; Sundström, T. (99m)Tc-DPD uptake reflects amyloid fibril composition in hereditary transthyretin amyloidosis. Ups. J. Med. Sci.,  2016, 121(1), 17-24.
[http://dx.doi.org/10.3109/03009734.2015.1122687] [PMID: 26849806] 
[52] 
Sperry, B.W.; Gonzalez, M.H.; Brunken, R.; Cerqueira, M.D.; Hanna, M.; Jaber, W.A. Non-cardiac uptake of technetium-99m pyrophosphate in transthyretin cardiac amyloidosis. J. Nucl. Cardiol.,  2019, 26(5), 1630-1637.
[http://dx.doi.org/10.1007/s12350-017-1166-7] [PMID: 29344917] 
[53] 
Cappelli, F.; Gallini, C.; Di Mario, C.; Costanzo, E.N.; Vaggelli, L.; Tutino, F.; Ciaccio, A.; Bartolini, S.; Angelotti, P.; Frusconi, S.; Farsetti, S.; Vergaro, G.; Giorgetti, A.; Marzullo, P.; Genovesi, D.; Emdin, M.; Perfetto, F. Accuracy of 99mTc-Hydroxymethylene diphosphonate scintigraphy for diagnosis of transthyretin cardiac amyloidosis. J. Nucl. Cardiol.,  2019, 26(2), 497-504.
[http://dx.doi.org/10.1007/s12350-017-0922-z] [PMID: 28537040] 
[54] 
Cariou, E.; Bennani Smires, Y.; Victor, G.; Robin, G.; Ribes, D.; Pascal, P.; Petermann, A.; Fournier, P.; Faguer, S.; Roncalli, J.; Rousseau, H.; Chauveau, D.; Carrié, D.; Berry, I.; Galinier, M.; Lairez, O. Toulouse Amyloidosis Research Network collaborators.. Diagnostic score for the detection of cardiac amyloidosis in patients with left ventricular hypertrophy and impact on prognosi. Amyloid,  2017, 24(2), 101-109.
[http://dx.doi.org/10.1080/13506129.2017.1333956] [PMID: 28553897] 
[55] 
Galat, A.; Rosso, J.; Guellich, A.; Van Der Gucht, A.; Rappeneau, S.; Bodez, D.; Guendouz, S.; Tissot, C.M.; Hittinger, L.; Dubois-Randé, J.L.; Plante-Bordeneuve, V.; Itti, E.; Meignan, M.; Damy, T. Usefulness of (99m)Tc-HMDP scintigraphy for the etiologic diagnosis and prognosis of cardiac amyloidosis. Amyloid,  2015, 22(4), 210-220.
[http://dx.doi.org/10.3109/13506129.2015.1072089] [PMID: 26465835] 
[56] 
Damy, T.; Judge, D.P.; Kristen, A.V.; Berthet, K.; Li, H.; Aarts, J. Cardiac findings and events observed in an open-label clinical trial of tafamidis in patients with non-Val30Met and non-Val122Ile hereditary transthyretin amyloidosis. J. Cardiovasc. Transl. Res.,  2015, 8(2), 117-127.
[http://dx.doi.org/10.1007/s12265-015-9613-9] [PMID: 25743445] 
[57] 
Van Der Gucht, A.; Cottereau, A.S.; Abulizi, M.; Guellich, A.; Blanc-Durand, P.; Israel, J.M.; Galat, A.; Plante-Bordeneuve, V.; Dubois-Randé, J.L.; Bodez, D.; Rosso, J.; Damy, T.; Itti, E. Apical sparing pattern of left ventricular myocardial 99mTc-HMDP uptake in patients with transthyretin cardiac amyloidosis. J. Nucl. Cardiol.,  2018, 25(6), 2072-2079.
[http://dx.doi.org/10.1007/s12350-017-0894-z] [PMID: 28447284] 
[58] 
Cappelli, F.; Gallini, C.; Costanzo, E.N.; Tutino, F.; Ciaccio, A.; Vaggelli, L.; Bartolini, S.; Morini, S.; Martone, R.; Angelotti, P.; Frusconi, S.; Di Mario, C.; Perfetto, F. Lung uptake during 99mTc-hydroxymethylene diphosphonate scintigraphy in patient with TTR cardiac amyloidosis: An underestimated phenomenon. Int. J. Cardiol.,  2018, 254, 346-350.
[http://dx.doi.org/10.1016/j.ijcard.2017.10.027] [PMID: 29407121] 
[59] 
Eriksson, P.; Backman, C.; Bjerle, P.; Eriksson, A.; Holm, S.; Olofsson, B.O. Non-invasive assessment of the presence and severity of cardiac amyloidosis. A study in familial amyloidosis with polyneuropathy by cross sectional echocardiography and technetium-99m pyrophosphate scintigraphy. Br. Heart J.,  1984, 52(3), 321-326.
[http://dx.doi.org/10.1136/hrt.52.3.321] [PMID: 6087862] 
[60] 
Falk, R.H.; Lee, V.W.; Rubinow, A.; Hood, W.B., Jr; Cohen, A.S. Sensitivity of technetium-99m-pyrophosphate scintigraphy in diagnosing cardiac amyloidosis. Am. J. Cardiol.,  1983, 51(5), 826-830.
[http://dx.doi.org/10.1016/S0002-9149(83)80140-4] [PMID: 6299087] 
[61] 
Gertz, M.A.; Brown, M.L.; Hauser, M.F.; Kyle, R.A. Utility of technetium Tc 99m pyrophosphate bone scanning in cardiac amyloidosis. Arch. Intern. Med.,  1987, 147(6), 1039-1044.
[http://dx.doi.org/10.1001/archinte.1987.00370060035007] [PMID: 3036031] 
[62] 
Wizenberg, T.A.; Muz, J.; Sohn, Y.H.; Samlowski, W.; Weissler, A.M. Value of positive myocardial technetium-99m-pyrophosphate scintigraphy in the noninvasive diagnosis of cardiac amyloidosis. Am. Heart J.,  1982, 103(4 Pt 1), 468-473.
[http://dx.doi.org/10.1016/0002-8703(82)90331-3] [PMID: 6278906] 
[63] 
Yamamoto, Y.; Onoguchi, M.; Haramoto, M.; Kodani, N.; Komatsu, A.; Kitagaki, H.; Tanabe, K. Novel method for quantitative evaluation of cardiac amyloidosis using (201)TlCl and (99m)Tc-PYP SPECT. Ann. Nucl. Med.,  2012, 26(8), 634-643.
[http://dx.doi.org/10.1007/s12149-012-0627-y] [PMID: 22777859] 
[64] 
Bokhari, S.; Morgenstern, R.; Weinberg, R.; Kinkhabwala, M.; Panagiotou, D.; Castano, A.; DeLuca, A.; Kontak, A.; Jin, Z.; Maurer, M.S. Standardization of 99mTechnetium pyrophosphate imaging methodology to diagnose TTR cardiac amyloidosis. J. Nucl. Cardiol.,  2018, 25(1), 181-190.
[http://dx.doi.org/10.1007/s12350-016-0610-4] [PMID: 27580616] 
[65] 
Castaño, A.; DeLuca, A.; Weinberg, R.; Pozniakoff, T.; Blaner, W.S.; Pirmohamed, A.; Bettencourt, B.; Gollob, J.; Karsten, V.; Vest, J.A.; Chiuzan, C.; Maurer, M.S.; Bokhari, S. Serial scanning with technetium pyrophosphate (99mTc-PYP) in advanced ATTR cardiac amyloidosis. J. Nucl. Cardiol.,  2016, 23(6), 1355-1363.
[http://dx.doi.org/10.1007/s12350-015-0261-x] [PMID: 26453570] 
[66] 
Haq, M.; Pawar, S.; Berk, J.L.; Miller, E.J.; Ruberg, F.L. Can 99mTc-pyrophosphate aid in early detection of cardiac involvement in asymptomatic variant TTR amyloidosis? JACC Cardiovasc. Imaging,  2017, 10(6), 713-714.
[http://dx.doi.org/10.1016/j.jcmg.2016.06.003] [PMID: 27568122] 
[67] 
Sperry, B.W.; Vranian, M.N.; Tower-Rader, A.; Hachamovitch, R.; Hanna, M.; Brunken, R.; Phelan, D.; Cerqueira, M.D.; Jaber, W.A. Regional variation in technetium pyrophosphate uptake in transthyretincardiac amyloidosis andImpact onmortality. JACC Cardiovasc. Imaging,  2018, 11(2 Pt 1), 234-242.
[http://dx.doi.org/10.1016/j.jcmg.2017.06.020] [PMID: 28917675] 
[68] 
Ochi, Y.; Kubo, T.; Nakashima, Y.; Baba, Y.; Hirota, T.; Yamasaki, N. Integrated diagnostic approach to wild-type transthyretin cardiac amyloidosis with the use of high-sensitivity cardiac troponin T measurement and 99mTc-pyrophosphate scintigraphy. J. Cardiol.,  2020, 75(1), 12-19.
[http://dx.doi.org/10.1016/j.jjcc.2019.05.011] [PMID: 31324572] 
[69] 
Goldstein, D.S. Cardiac dysautonomia and survival in hereditary transthyretin amyloidosis. JACC Cardiovasc. Imaging,  2016, 9(12), 1442-1445.
[http://dx.doi.org/10.1016/j.jcmg.2016.08.003] [PMID: 27838301] 
[70] 
Falk, R.H.; Comenzo, R.L.; Skinner, M. The systemic amyloidoses. N. Engl. J. Med.,  1997, 337(13), 898-909.
[http://dx.doi.org/10.1056/NEJM199709253371306] [PMID: 9302305] 
[71] 
Bokhari, S.; Shahzad, R.; Castaño, A.; Maurer, M.S. Nuclear imaging modalities for cardiac amyloidosis. J. Nucl. Cardiol.,  2014, 21(1), 175-184.
[http://dx.doi.org/10.1007/s12350-013-9803-2] [PMID: 24162886] 
[72] 
Chen, W.; Cao, Q.; Dilsizian, V. Variation of heart-to-mediastinal ratio in (123)I-mIBG cardiac sympathetic imaging: its affecting factors and potential corrections. Curr. Cardiol. Rep.,  2011, 13(2), 132-137.
[http://dx.doi.org/10.1007/s11886-010-0157-y] [PMID: 21221858] 
[73] 
Nakata, T.; Shimamoto, K.; Yonekura, S.; Kobayashi, N.; Sugiyama, T.; Imai, K.; Iimura, O. Cardiac sympathetic denervation in transthyretin-related familial amyloidotic polyneuropathy: detection with iodine-123-MIBG. J. Nucl. Med.,  1995, 36(6), 1040-1042.
[PMID: 7769425] 
[74] 
Delahaye, N.; Dinanian, S.; Slama, M.S.; Mzabi, H.; Samuel, D.; Adams, D.; Merlet, P.; Le Guludec, D. Cardiac sympathetic denervation in familial amyloid polyneuropathy assessed by iodine-123 metaiodobenzylguanidine scintigraphy and heart rate variability. Eur. J. Nucl. Med.,  1999, 26(4), 416-424.
[http://dx.doi.org/10.1007/s002590050406] [PMID: 10199949] 
[75] 
Tanaka, M.; Hongo, M.; Kinoshita, O.; Takabayashi, Y.; Fujii, T.; Yazaki, Y.; Isobe, M.; Sekiguchi, M. Iodine-123 metaiodobenzylguanidine scintigraphic assessment of myocardial sympathetic innervation in patients with familial amyloid polyneuropathy. J. Am. Coll. Cardiol.,  1997, 29(1), 168-174.
[http://dx.doi.org/10.1016/S0735-1097(96)00438-X] [PMID: 8996310] 
[76] 
Noordzij, W.; Glaudemans, A.W.; van Rheenen, R.W.; Hazenberg, B.P.; Tio, R.A.; Dierckx, R.A.; Slart, R.H. (123)I-Labelled metaiodobenzylguanidine for the evaluation of cardiac sympathetic denervation in early stage amyloidosis. Eur. J. Nucl. Med. Mol. Imaging,  2012, 39(10), 1609-1617.
[http://dx.doi.org/10.1007/s00259-012-2187-8] [PMID: 22806059] 
[77] 
Piekarski, E.; Chequer, R.; Algalarrondo, V.; Eliahou, L.; Mahida, B.; Vigne, J.; Adams, D.; Slama, M.S.; Le Guludec, D.; Rouzet, F. Cardiac denervation evidenced by MIBG occurs earlier than amyloid deposits detection by diphosphonate scintigraphy in TTR mutation carriers. Eur. J. Nucl. Med. Mol. Imaging,  2018, 45(7), 1108-1118.
[http://dx.doi.org/10.1007/s00259-018-3963-x] [PMID: 29511839] 
[78] 
Jonker, D.L.; Hazenberg, B.P.C.; Nienhuis, H.L.A.; Slart, R.H.J.A.; Glaudemans, A.W.J.M.; Noordzij, W. Imaging cardiac innervation in hereditary transthyretin (ATTRm) amyloidosis: A marker for neuropathy or cardiomyopathy in case of heart failure? J. Nucl. Cardiol.,  2020, 27(5), 1774-1784.
[http://dx.doi.org/10.1007/s12350-018-01477-y] [PMID: 30374850] 
[79] 
Algalarrondo, V.; Antonini, T.; Théaudin, M.; Chemla, D.; Benmalek, A.; Lacroix, C.; Castaing, D.; Cauquil, C.; Dinanian, S.; Eliahou, L.; Samuel, D.; Adams, D.; Le Guludec, D.; Slama, M.S.; Rouzet, F. Cardiac Dysautonomia Predicts Long-Term Survival in Hereditary Transthyretin Amyloidosis After LiverTransplantation. JACC Cardiovasc. Imaging,  2016, 9(12), 1432-1441.
[http://dx.doi.org/10.1016/j.jcmg.2016.07.008] [PMID: 27838303] 
[80] 
Coutinho, M.C.; Cortez-Dias, N.; Cantinho, G.; Conceição, I.; Oliveira, A.; Bordalo e Sá, A.; Gonçalves, S.; Almeida, A.G.; de Carvalho, M.; Diogo, A.N. Reduced myocardial 123-iodine metaiodobenzylguanidine uptake: a prognostic marker in familial amyloid polyneuropathy. Circ Cardiovasc Imaging,  2013, 6(5), 627-636.
[http://dx.doi.org/10.1161/CIRCIMAGING.112.000367] [PMID: 23833285] 
[81] 
Delahaye, N.; Rouzet, F.; Sarda, L.; Tamas, C.; Dinanian, S.; Plante-Bordeneuve, V.; Adams, D.; Samuel, D.; Merlet, P.; Syrota, A.; Slama, M.S.; Le Guludec, D. Impact of liver transplantation on cardiac autonomic denervation in familial amyloid polyneuropathy. Medicine (Baltimore),  2006, 85(4), 229-238.
[http://dx.doi.org/10.1097/01.md.0000232559.22098.c3] [PMID: 16862048] 
[82] 
Hongo, M.; Urushibata, K.; Kai, R.; Takahashi, W.; Koizumi, T.; Uchikawa, S.; Imamura, H.; Kinoshita, O.; Owa, M.; Fujii, T. Iodine-123 metaiodobenzylguanidine scintigraphic analysis of myocardial sympathetic innervation in patients with AL (primary) amyloidosis. Am. Heart J.,  2002, 144(1), 122-129.
[http://dx.doi.org/10.1067/mhj.2002.123115] [PMID: 12094198] 
[83] 
Singh, V.; Falk, R.; Di Carli, M.F.; Kijewski, M.; Rapezzi, C.; Dorbala, S. State-of-the-art radionuclide imaging in cardiac transthyretin amyloidosis. J. Nucl. Cardiol.,  2019, 26(1), 158-173.
[http://dx.doi.org/10.1007/s12350-018-01552-4] [PMID: 30569412] 
[84] 
Antoni, G.; Lubberink, M.; Estrada, S.; Axelsson, J.; Carlson, K.; Lindsjö, L.; Kero, T.; Långström, B.; Granstam, S.O.; Rosengren, S.; Vedin, O.; Wassberg, C.; Wikström, G.; Westermark, P.; Sörensen, J. In vivo visualization of amyloid deposits in the heart with 11C-PIB and PET. J. Nucl. Med.,  2013, 54(2), 213-220.
[http://dx.doi.org/10.2967/jnumed.111.102053] [PMID: 23238792] 
[85] 
Ezawa, N.; Katoh, N.; Oguchi, K.; Yoshinaga, T.; Yazaki, M.; Sekijima, Y. Visualization of multiple organ amyloid involvement in systemic amyloidosis using 11C-PiB PET imaging. Eur. J. Nucl. Med. Mol. Imaging,  2018, 45(3), 452-461.
[http://dx.doi.org/10.1007/s00259-017-3814-1] [PMID: 28891012] 
[86] 
Lee, S.P.; Lee, E.S.; Choi, H.; Im, H.J.; Koh, Y.; Lee, M.H.; Kwon, J.H.; Paeng, J.C.; Kim, H.K.; Cheon, G.J.; Kim, Y.J.; Kim, I.; Yoon, S.S.; Seo, J.W.; Sohn, D.W. 11C-Pittsburgh B PET imaging in cardiac amyloidosis. JACC Cardiovasc. Imaging,  2015, 8(1), 50-59.
[http://dx.doi.org/10.1016/j.jcmg.2014.09.018] [PMID: 25499132] 
[87] 
Kero, T.; Lindsjö, L.; Sörensen, J.; Lubberink, M. Accurate analysis and visualization of cardiac (11)C-PIB uptake in amyloidosis with semiautomatic software. J. Nucl. Cardiol.,  2016, 23(4), 741-750.
[http://dx.doi.org/10.1007/s12350-015-0149-9] [PMID: 26173894] 
[88] 
Minamimoto, R.; Awaya, T.; Iwama, K.; Hotta, M.; Nakajima, K.; Hirai, R. Significance of 11C-PIB PET/CT in cardiac amyloidosis compared with 99mTc-aprotinin scintigraphy: A pilot study. J. Nucl. Cardiol.,  2020, 27(1), 202-209.
[http://dx.doi.org/10.1007/s12350-018-1260-5] [PMID: 29589208] 
[89] 
Dorbala, S.; Vangala, D.; Semer, J.; Strader, C.; Bruyere, J.R., Jr; Di Carli, M.F.; Moore, S.C.; Falk, R.H. Imaging cardiac amyloidosis: a pilot study using ¹⁸F-florbetapir positron emission tomography. Eur. J. Nucl. Med. Mol. Imaging,  2014, 41(9), 1652-1662.
[http://dx.doi.org/10.1007/s00259-014-2787-6] [PMID: 24841414] 
[90] 
Law, W.P.; Wang, W.Y.; Moore, P.T.; Mollee, P.N.; Ng, A.C. Cardiac Amyloid Imaging with 18F-Florbetaben PET: A Pilot Study. J. Nucl. Med.,  2016, 57(11), 1733-1739.
[http://dx.doi.org/10.2967/jnumed.115.169870] [PMID: 27307344] 
[91] 
Park, M.A.; Padera, R.F.; Belanger, A.; Dubey, S.; Hwang, D.H.; Veeranna, V.; Falk, R.H.; Di Carli, M.F.; Dorbala, S. 18F-Florbetapir binds specifically to myocardial light chain and transthyretin amyloid deposits: autoradiography study. Circ Cardiovasc Imaging,  2015, 8(8)e002954
[http://dx.doi.org/10.1161/CIRCIMAGING.114.002954] [PMID: 26259579] 
[92] 
Osborne, D.R.; Acuff, S.N.; Stuckey, A.; Wall, J.S. A routine PET/CT protocol with streamlined calculations for assessing cardiac amyloidosis using (18)F-Florbetapir. Front. Cardiovasc. Med.,  2015, 2, 23.
[http://dx.doi.org/10.3389/fcvm.2015.00023] [PMID: 26664895] 
[93] 
Pilebro, B.; Arvidsson, S.; Lindqvist, P.; Sundström, T.; Westermark, P.; Antoni, G.; Suhr, O.; Sörensen, J. Positron emission tomography (PET) utilizing Pittsburgh compound B (PIB) for detection of amyloid heart deposits in hereditary transthyretin amyloidosis (ATTR). J. Nucl. Cardiol.,  2018, 25(1), 240-248.
[http://dx.doi.org/10.1007/s12350-016-0638-5] [PMID: 27645889] 
[94] 
Kim, Y.J.; Ha, S.; Kim, Y.I. Cardiac amyloidosis imaging with amyloid positron emission tomography: A systematic review and meta-analysis. J. Nucl. Cardiol.,  2020, 27(1), 123-132.
[http://dx.doi.org/10.1007/s12350-018-1365-x] [PMID: 30022405] 
[95] 
Manwani, R.; Page, J.; Lane, T.; Burniston, M.; Skillen, A.; Lachmann, H.J.; Gillmore, J.D.; Fontana, M.; Whelan, C.; Hawkins, P.N.; Wagner, T.; Wechalekar, A.D. A pilot study demonstrating cardiac uptake with 18F-florbetapir PET in AL amyloidosis patients with cardiac involvement. Amyloid,  2018, 25(4), 247-252.
[http://dx.doi.org/10.1080/13506129.2018.1552852] [PMID: 30661419] 
[96] 
Kircher, M.; Ihne, S.; Brumberg, J.; Morbach, C.; Knop, S.; Kortüm, K.M.; Störk, S.; Buck, A.K.; Reiter, T.; Bauer, W.R.; Lapa, C. Detection of cardiac amyloidosis with 18F-Florbetaben-PET/CT in comparison to echocardiography, cardiac MRI and DPD-scintigraphy. Eur. J. Nucl. Med. Mol. Imaging,  2019, 46(7), 1407-1416.
[http://dx.doi.org/10.1007/s00259-019-04290-y] [PMID: 30798427] 
[97] 
Baratto, L.; Park, S.Y.; Hatami, N.; Gulaka, P.; Vasanawala, S.; Yohannan, T.K.; Herfkens, R.; Witteles, R.; Iagaru, A. 18F-florbetaben whole-body PET/MRI for evaluation of systemic amyloid deposition. EJNMMI Res.,  2018, 8(1), 66.
[http://dx.doi.org/10.1186/s13550-018-0425-1] [PMID: 30043115] 
[98] 
Mestre-Torres, J.; Lorenzo-Bosquet, C.; Cuberas-Borrós, G.; Gironella, M.; Solans-Laque, R.; Fernández-Codina, A.; Bujan-Rivas, S.; Castell-Conesa, J.; Martínez-Valle, F. Utility of the 18F-Florbetapir positron emission tomography in systemic amyloidosis. Amyloid,  2018, 25(2), 109-114.
[http://dx.doi.org/10.1080/13506129.2018.1467313] [PMID: 29706127] 
[99] 
Wagner, T.; Page, J.; Burniston, M.; Skillen, A.; Ross, J.C.; Manwani, R.; McCool, D.; Hawkins, P.N.; Wechalekar, A.D. Extracardiac 18F-florbetapir imaging in patients with systemic amyloidosis: more than hearts and minds. Eur. J. Nucl. Med. Mol. Imaging,  2018, 45(7), 1129-1138.
[http://dx.doi.org/10.1007/s00259-018-3995-2] [PMID: 29651545] 
[100] 
Ehman, E.C.; El-Sady, M.S.; Kijewski, M.F.; Khor, Y.M.; Jacob, S.; Ruberg, F.L.; Sanchorawala, V.; Landau, H.; Yee, A.J.; Bianchi, G.; Di Carli, M.F.; Falk, R.H.; Hyun, H.; Dorbala, S. Early Detection of multiorgan light-chain amyloidosis by whole-body 18F-Florbetapir PET/CT. J. Nucl. Med.,  2019, 60(9), 1234-1239.
[http://dx.doi.org/10.2967/jnumed.118.221770] [PMID: 30954943] 
[101] 
Van Der Gucht, A.; Galat, A.; Rosso, J.; Guellich, A.; Garot, J.; Bodez, D.; Plante-Bordeneuve, V.; Hittinger, L.; Dubois-Randé, J.L.; Evangelista, E.; Sasanelli, M.; Chalaye, J.; Meignan, M.; Itti, E.; Damy, T. [18F]-NaF PET/CT imaging in cardiac amyloidosis. J. Nucl. Cardiol.,  2016, 23(4), 846-849.
[http://dx.doi.org/10.1007/s12350-015-0287-0] [PMID: 26403145] 
[102] 
Gagliardi, C.; Tabacchi, E.; Bonfiglioli, R.; Diodato, S.; Nanni, C.; Guidalotti, P.; Lorenzini, M.; Lodi, F.; Milandri, A.; Rapezzi, C.; Fanti, S. Does the etiology of cardiac amyloidosis determine the myocardial uptake of [18F]-NaF PET/CT? J. Nucl. Cardiol.,  2017, 24(2), 746-749.
[http://dx.doi.org/10.1007/s12350-016-0457-8] [PMID: 26976144] 
[103] 
Morgenstern, R.; Yeh, R.; Castano, A.; Maurer, M.S.; Bokhari, S. 18Fluorine sodium fluoride positron emission tomography, a potential biomarker of transthyretin cardiac amyloidosis. J. Nucl. Cardiol.,  2018, 25(5), 1559-1567.
[http://dx.doi.org/10.1007/s12350-017-0799-x] [PMID: 28176254] 
[104] 
Trivieri, M.G.; Dweck, M.R.; Abgral, R.; Robson, P.M.; Karakatsanis, N.A.; Lala, A.; Contreras, J.; Sahni, G.; Gopalan, R.; Gorevic, P.; Fuster, V.; Narula, J.; Fayad, Z.A. 18F-Sodium Fluoride PET/MR for the Assessment of CardiacAmyloidosis. J. Am. Coll. Cardiol.,  2016, 68(24), 2712-2714.
[http://dx.doi.org/10.1016/j.jacc.2016.09.953] [PMID: 27978955] 
[105] 
Martineau, P.; Finnerty, V.; Giraldeau, G.; Authier, S.; Harel, F.; Pelletier-Galarneau, M. Examining the sensitivity of 18F-NaF PET for the imaging of cardiac amyloidosis. J. Nucl. Cardiol.,  2019, •••
[http://dx.doi.org/10.1007/s12350-019-01675-2] [PMID: 30834499] 
[106] 
Abulizi, M.; Sifaoui, I.; Wuliya-Gariepy, M.; Kharoubi, M.; Israël, J.M.; Emsen, B.; Bodez, D.; Monnet, A.; Didierlaurent, D.; Tacher, V.; Luciani, A.; Damy, T.; Deux, J.F.; Itti, E. 18F-sodium fluoride PET/MRI myocardial imaging in patients with suspected cardiac amyloidosis. J. Nucl. Cardiol., 2019.
[http://dx.doi.org/10.1007/s12350-019-01885-8] [PMID: 31512197] 
Rights & Permissions Print Cite
Article Metrics
34
Journal Information
For Authors
For Editors
For Reviewers
Explore Articles
Open Access
Open Access Articles
For Visitors
DOI https://dx.doi.org/10.2174/1874471013666200611105856	Print ISSN 1874-4710
Publisher Name Bentham Science Publisher	Online ISSN 1874-4729
Current Radiopharmaceuticals

The Role of Molecular Imaging in the Assessment of Cardiac Amyloidosis: State-of-the-Art

Abstract

Graphical Abstract

Related Journals

Related Books

Related Articles
